Azanta is a specialty pharma company with primary focus on Oncology. Azanta's portfolio of specialty pharma products funds the development of proprietary cancer products from late stage drug development through to registration.
Azanta is dedicated to health which predominantly and historically has led us to focus our efforts on women's health care. Azanta has a string of products addressing women's needs. We constantly strive to broaden our portfolio of products to address unmet medical needs which also include focus on men'shealth.
Making available substitution medicine for drug addicts is a niche focus of Azanta's specialty pharma company. Azanta is dedicated to serve the National Health Authorities in providing treatment that improves people's quality of life on a daily basis.
Azanta is an international specialty pharma company with focus on marketing specialty pharma products in the Nordic Countries. Azanta operates primarily within oncology, women's healthcare and addiction medicine, and currently markets a string of specialty pharma products. Constantly, Azanta looks for new licensing opportunities and partners with products to supplement and broaden the products in our existing portfolio and that at the same time addresses unmet treatment needs. Azanta's portfolio of specialty pharma products funds the development of proprietary key cancer products from late stage drug development through to registration. Azanta's cancer drug development portfolio encompasses orphan designated products addressing unmet medical needs. Until registration, these products are made available within and beyond Europe on a compassionate use basis.
In addition, Azanta manufacture and register own niche specialty pharma products for near term commercialization.
2013-09-30New Cancer Treatment Available in the United Kingdom
Hellerup, Denmark, September 30, 2013. Azanta A/S, a ...
2013-05-27Azanta at the Anglonordic Conference 2013
Hellerup, Denmark; May 27, 2013 - Azanta A/S announced today it will attend the Anglonordic B...
2013-04-17Azanta receives scientific advice from EMA for Phase III registration study with Nimoral
Summary: Azanta has received scientific advice from EMA concerning the upcoming registration ...